

1 **CD177, a specific marker of neutrophil activation, is a hallmark of COVID-19 severity**  
2 **and death**

3 Yves Lévy<sup>1,2\*</sup>, Aurélie Wiedemann<sup>1‡</sup>, Boris P. Hejblum<sup>1,3‡</sup>, Mélanie Durand<sup>1,3</sup>, Cécile  
4 Lefebvre<sup>1</sup>, Mathieu Surénaud<sup>1</sup>, Christine Lacabartz<sup>1</sup>, Matthieu Perreau<sup>4</sup>, Emile Foucat<sup>1</sup>,  
5 Marie Déchenaud<sup>1</sup>, Pascaline Tisserand<sup>1</sup>, Fabiola Blengio<sup>1</sup>, Benjamin Hivert<sup>3</sup>, Marine  
6 Gautier<sup>3</sup>, Minerva Cervantes-Gonzalez<sup>5,6,7</sup>, Delphine Bachelet<sup>5,7</sup>, Cédric Laouénan<sup>5,7</sup>, Lila  
7 Bouadma<sup>8</sup>, Jean-François Timsit<sup>8</sup>, Yazdan Yazdanpanah<sup>6,7</sup>, Giuseppe Pantaleo<sup>1,4,9</sup>, Hakim  
8 Hocini<sup>1†</sup>, Rodolphe Thiébaud<sup>1,3,10\*†</sup> and the French COVID cohort study group<sup>a</sup>

9 *Affiliations*

- 10 1. Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine,  
11 INSERM U955, Team 16, Créteil, France.
- 12 2. Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier,  
13 Service Immunologie Clinique, Créteil, France
- 14 3. Univ. Bordeaux, Department of Public Health, Inserm Bordeaux Population Health  
15 Research Centre, Inria SISTM, UMR 1219; Bordeaux, France
- 16 4. Swiss Vaccine Research Institute, Lausanne University Hospital, University of  
17 Lausanne, Lausanne, Switzerland
- 18 5. AP-HP, Hôpital Bichat, Département Épidémiologie Biostatistiques et Recherche  
19 Clinique, INSERM, Centre d'Investigation clinique-Epidémiologie Clinique 1425  
20 F-75018 Paris, France
- 21 6. AP-HP, Hôpital Bichat, Service de Maladies Infectieuses et Tropicales, F-75018  
22 Paris, France
- 23 7. Université de Paris, INSERM, IAME UMR 1137, F-75018 Paris, France
- 24 8. APHP- Hôpital Bichat – Médecine Intensive et Réanimation des Maladies  
25 Infectieuses, Paris, France
- 26 9. Immunology and Allergy Service, Department of Medicine; Lausanne University  
27 Hospital, University of Lausanne, Lausanne, Switzerland.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 10. CHU de Bordeaux, Pôle de Santé Publique, Service d'Information Médicale,  
29 Bordeaux, France

30 **\*Correspondence:** Pr. Yves Lévy, Vaccine Research Institute, INSERM U955, Hopital Henri  
31 Mondor, 51 Av Marechal de Lattre de Tassigny, 94010 Créteil, France, Phone: +33 (0) 1 49  
32 81 44 42, Fax: +33 (0) 1 49 81 24 69, E-mail: [yves.levy@aphp.fr](mailto:yves.levy@aphp.fr) & Pr Rodolphe Thiébaud,  
33 Université de Bordeaux, INSERM U1219 Bordeaux Population Health, 146 Rue Leo Saignat  
34 33076 Bordeaux Cedex, France, Phone : +33 (0) 5 57 57 45 21, Fax : +33 (0) 5 56 24 00 81,  
35 E-mail: [rodolphe.thiebaut@u-bordeaux.fr](mailto:rodolphe.thiebaut@u-bordeaux.fr)

36 ‡these authors contributed equally to this work

37 † co-last authors

38 <sup>a</sup> Members of the French COVID study group are in listed in Supplementary Information

39

40 **Abstract**

41 COVID-19 SARS-CoV-2 infection exhibits wide inter-individual clinical variability, from silent  
42 infection to severe disease and death. The identification of high-risk patients is a continuing  
43 challenge in routine care. We aimed to identify factors that influence clinical worsening. We  
44 analyzed 52 cell populations, 71 analytes, and RNA-seq gene expression in the blood of  
45 severe patients from the French COVID cohort upon hospitalization (n = 61). COVID-19  
46 patients showed severe abnormalities of 27 cell populations relative to healthy donors (HDs).  
47 Forty-two cytokines, neutrophil chemo-attractants, and inflammatory components were  
48 elevated in COVID-19 patients. Supervised gene expression analyses showed differential  
49 expression of genes for neutrophil activation, interferon signaling, T- and B-cell receptors, EIF2  
50 signaling, and ICOS-ICOSL pathways in COVID-19 patients. Unsupervised analysis confirmed  
51 the prominent role of neutrophil activation, with a high abundance of CD177, a specific  
52 neutrophil activation marker. CD177 was the most highly differentially-expressed gene  
53 contributing to the clustering of severe patients and its abundance correlated with CD177  
54 protein serum levels. CD177 levels were higher in COVID-19 patients from both the French  
55 and “confirmatory” Swiss cohort (n = 203) than in HDs ( $P < 0.01$ ) and in ICU than non-ICU  
56 patients ( $P < 0.001$ ), correlating with the time to symptoms onset ( $P = 0.002$ ). Longitudinal  
57 measurements showed sustained levels of serum CD177 to discriminate between patients with  
58 the worst prognosis, leading to death, and those who recovered ( $P = 0.01$ ). These results  
59 highlight neutrophil activation as a hallmark of severe disease and CD177 assessment as a  
60 reliable prognostic marker for routine care.

61

## 62 Introduction

63 The Coronavirus Disease 2019 (COVID-19) pandemic is caused by a newly described highly  
64 pathogenic beta coronavirus, Severe Acute Respiratory Syndrome coronavirus 2 (SARS-  
65 CoV-2) <sup>1,2</sup>. COVID-19 consists of a spectrum of clinical symptoms that range from mild upper  
66 respiratory tract disease in most cases to severe disease that affects approximately 15% of  
67 patients requiring hospitalization <sup>3</sup>, some of whom require intensive care because of severe  
68 lower respiratory tract illness, acute respiratory distress syndrome (ARDS), and extra-  
69 pulmonary manifestations, leading to multi-organ failure and death. Several recent studies  
70 have provided important clues about the pathophysiology of COVID-19 <sup>4-8</sup>. Most compared  
71 the immune and inflammatory status of patients at different stages of the disease <sup>9-11</sup>. Thus,  
72 several important biomarkers associated with specific phases of the evolution of COVID-19  
73 have thus far been identified <sup>12,13</sup>. Inflammation, cytokine storms, and other dysregulated  
74 immune responses have been shown to be associated with severe disease pathogenesis  
75 <sup>14,15</sup>. Severe COVID-19 patients are characterized by elevated numbers of monocytes and  
76 neutrophils and lymphopenia <sup>10,16-18</sup>, and a high neutrophil to lymphocyte ratio predicts in-  
77 hospital mortality of critically-ill patients <sup>19</sup>. High levels of pro-inflammatory cytokines,  
78 including IL-6, IL-1 $\beta$ , TNF, MCP-1, IP-10, and G-CSF, in the plasma <sup>5,10,16,18,20</sup> and a possible  
79 defect in type I interferon activity have been reported in patients with severe COVID-19 <sup>9,15,21</sup>.  
80 However, these responses are dynamic, changing rapidly during the clinical course of the  
81 disease, which may explain the high variability of the immunological spectrum described  
82 <sup>14,21,22</sup>. This makes it difficult to deduce a unique profile of the pathophysiology of this  
83 infection, which is still undetermined. Furthermore, the high amplitude of the signals  
84 generated by the inflammation associated with the disease may hide other pathways that are  
85 involved.

86 From a clinical standpoint, clinicians face the daily challenge of predicting worsening patients  
87 due to the peculiar clinical course of severe COVID-19, characterized by a sudden  
88 deterioration of the clinical condition 7 to 8 days after the onset of symptoms. Determination

89 of the onset of the pathological process once infection has been established in a patient with  
90 a severe stage of infection is highly imprecise because of the possible pauci- or  
91 asymptomatic phase of the infection, as well as the low specificity of self-limited “flu” illness.

92 We used a systems immunology approach to identify host factors that were significantly  
93 associated with the time to illness onset, severity of the disease (ICU or transfer to ICU), and  
94 mortality of COVID-19 patients enrolled in the multicentric French COVID cohort <sup>23</sup>. In  
95 addition to the depletion of T cells and mobilization of B cells, neutrophil activation, and  
96 severe inflammation, we show upregulation of CD177 gene expression and protein levels in  
97 the blood of COVID-19 patients in both the COVID-19 cohort and a “confirmatory” cohort,  
98 i.e., Swiss cohort, relative to healthy subjects. CD177, a neutrophil activation marker,  
99 characterized critically ill patients and marked disease progression and death. Our finding  
100 highlights the major role of neutrophil activation through CD177 over-expression in the critical  
101 clinical transition point in the trajectory of COVID-19 patients.

102

103

## 104 **Results**

### 105 **Overview of the phenotype, cytokine, and inflammatory profiles of COVID-19 patients**

106 Patient characteristics from the French COVID cohort enrolled in this analysis are shown in  
107 Table 1. All patients from this cohort were stratified as severe according to criteria of the  
108 French COVID cohort (clinicaltrials.gov NCT04262921) <sup>23</sup>, with 53 (87%) hospitalized in an  
109 ICU (either initially or after clinical worsening or death) and eight not. The median age was  
110 60 years ([interquartile range (IQR)], [50-69]) and 80% were male. Sampling for  
111 immunological analyses was performed within three days of entry and after a median of 11  
112 days [7-14] after symptoms onset. We first assessed leukocyte profiles by flow cytometry  
113 using frozen peripheral blood mononuclear cells (PBMCs) from 50 COVID-19 patients (with  
114 available PBMC samples) and 18 healthy donors (HDs) (14 or 15 HDs were used as controls  
115 per immune-cell subset).

116 We analyzed 52 immune cell populations, of which 23 showed significant differences  
117 (Wilcoxon test adjusted for multiple comparisons) between the COVID-19 patients and HDs.  
118 We not only confirmed previously reported abnormalities but also revealed new  
119 immunological features of COVID-19 patients (supplementary Figure 1). The COVID-19  
120 patients showed a significant reduction in the frequency of total CD3<sup>+</sup> T cells and CD8<sup>+</sup> T  
121 cells relative to HDs, as previously reported <sup>24,25</sup>, that expressed an activated phenotype  
122 (CD38<sup>+</sup>HLA-DR<sup>+</sup>) (Figure 1A). The COVID-19 patients also showed lower frequencies of  
123 resting memory B cells contrasting with higher frequencies of activated memory B cells and  
124 exhausted B cells (Figure 1B). As previously reported <sup>10,22</sup>, the proportion of plasmablasts  
125 was markedly higher in COVID-19 patients (median [Q1-Q3]: 10.85% [3-23]) than HDs  
126 (0.76% [0.4-0.8]) (P < 0.001). Total NK-cell frequencies, more precisely those of the  
127 CD56<sup>bright</sup> and CD56<sup>dim</sup>CD57<sup>-</sup> NK-cell subpopulations, were lower than in HDs (P = 0.017, P <  
128 0.001, and P = 0.004, respectively) (Figure 1C), while a higher proportion of these NK cells,  
129 as well as NKT cells, were cycling, expressing Ki67 antigen (CD56<sup>bright</sup>: 22% [13-30],  
130 CD56<sup>dim</sup>CD57<sup>-</sup>: 16.8% [11.5-27], and NKT: 10% [5.6-18.2]) (P = 0.003, P = 0.004, and P =

131 0.001 compared to HD) (Figure 1C). In addition, COVID 19-patients showed significantly  
132 smaller classical (CD14<sup>+</sup>CD16<sup>-</sup>), intermediate (CD14<sup>+</sup>CD16<sup>+</sup>), and non-classical (CD14<sup>-</sup>  
133 CD16<sup>+</sup>) monocyte subpopulations than HDs (P = 0.013, P = 0.017, P < 0.001, respectively)  
134 (Figure 1D). Interestingly, COVID-19 patients tended to exhibit a higher frequency of  $\gamma\delta$  T  
135 cells than HDs (median 10.4% [7.5-16.1] vs 7.3% [6-10] in HDs; P = 0.068) (Figure 1E), with  
136 a significant proportion of  $\gamma\delta$  T cells showing higher expression of the activation marker  
137 CD16 (P = 0.01) and lower expression of the inhibitory receptor NKG2A (P < 0.001) than  
138 HDs (Figure 1E). Finally, we observed markedly smaller frequencies of dendritic cells (DCs)  
139 for all populations studied (pre-DC, plasmacytoid DC (pDC), and conventional DC (cDC1 and  
140 cDC2) in COVID-19 patients than in HDs (P < 0.001, for all comparisons) (Figure 1F).

141 We then evaluated the levels of 71 serum cytokines, chemokines, and inflammatory factors  
142 in 33 COVID-19 patients and 5 HDs. Forty-four analytes differed significantly (Wilcoxon test  
143 adjusted for multiple comparisons) between the COVID-19 patients and HDs (shown in the  
144 heatmap in Figure 2 and detailed in Supplementary Figure 2). The levels of 42 factors were  
145 higher, among them, pro-inflammatory factors (IL-1a, IL-6, IL-18, tumor necrosis factor- $\alpha$  and  
146  $\beta$  (TNF- $\alpha$ , TNF- $\beta$ ), IL-1ra, ST2/IL-1R4, the acute phase protein lipopolysaccharide binding  
147 protein LBP, IFN- $\alpha$ 2); Th1 pathway factors (IL-12 (p70), IFN- $\gamma$ , IP-10, IL-2Ra); Th2/regulatory  
148 cytokines (IL-4, IL-10, IL-13); IL-17, which also promotes granulocyte-colony stimulating  
149 factor (G-CSF)-mediated granulopoiesis and recruits neutrophils to inflammatory sites; T-cell  
150 proliferation and activation factors (IL-7, IL-15); growth factors (SCF, SCGF-b, HGF, b-FGF,  
151 b-NGF); and a significant number of cytokines and chemokines involved in macrophage and  
152 neutrophil activation and chemotaxis (RANTES (CCL5), MIP-1a and b (CCL3 and CCL4),  
153 MCP-1 (CCL2), MCP-3 (CCL7), M-CSF, MIF, Gro-a (CXCL1), monokine inducible by  $\gamma$   
154 interferon MIG/CXCL9, IL-8, IL-9). Interestingly, we found higher levels of midkine, a marker  
155 usually not detectable in the serum, which enhances the recruitment and migration of  
156 inflammatory cells and contributes to tissue damage<sup>26</sup>. In parallel, Granzyme B and IL-21

157 levels were significantly lower in COVID-19 patients than HDs ( $P = 0.007$  and  $P = 0.004$ ,  
158 respectively) (Supplementary Figure 2).

### 159 **Whole blood gene expression profiles show a specific signature for COVID-19 patients**

160 The comparison of gene abundance in whole blood between COVID-19 patients ( $n = 44$ ) and  
161 HDs ( $n = 10$ ) showed 4,079 differentially expressed genes (DEG) with an absolute fold  
162 change  $\geq 1.5$ , including 1,904 that were upregulated and 2,175 that were downregulated  
163 (Figure 3A). The main pathways associated with the DEG correspond to the immune  
164 response, including neutrophil and interferon signaling, T and B cell receptor responses,  
165 metabolism, protein synthesis, and regulators of the Eif2 and mammalian target of  
166 rapamycin (mTOR) signaling pathways (Figure 3A). Although several of these pathways  
167 involved multiple cell types, analysis of the neutrophil pathway showed higher abundance of  
168 genes mainly related to neutrophil activation, their interaction with endothelial cells, and  
169 migration (Figure 3B). Among the most highly expressed genes, this signature included  
170 CD177, a specific marker of neutrophil adhesion to the endothelium and transmigration <sup>27</sup>,  
171 HP (Haptoglobin), a marker of granulocyte differentiation and released by neutrophils in  
172 response to activation <sup>28</sup>, VNN1 (hematopoietic cell trafficking), GPR84 (neutrophil  
173 chemotaxis), MMP9 (neutrophil activation and migration), and S100A8 and S100A12  
174 (neutrophil recruitment, chemotaxis, and migration). The S100A12 protein is produced  
175 predominantly by neutrophils and is involved in inflammation and the upregulation of vascular  
176 endothelial cell adhesion molecules <sup>29</sup> (Figure 3B).

177 In parallel, we observed a higher abundance of several interferon stimulating genes (ISG)  
178 (IFI27, IFITM3, IFITM1, IFITM2, IFI6, IRF7, IRF4) (Figure 3C) and cytokines and cytokine  
179 receptors (IL-1R, IL-18R1, IL-18RAP, IL-4R, IL-17R, IL-10) (Figure 3D). Consistent with  
180 profound T-cell lymphopenia, the expression of several families of T-cell Receptor (TCRA)  
181 genes was lower (Figure 3E). We observed severe dysregulation of T-cell function that  
182 involved inhibition of serine/threonine kinase PKC $\theta$  signaling (z-score = -4.46) (data not  
183 shown), as well as the inducible T-cell co-stimulator/ICOSL axis (z-score = -4.5)

184 (Supplementary Figure 3). In contrast to the results for T cells, the peripheral expansion of  
185 memory B cells and plasmablasts was associated with broad expansion of the B-Cell  
186 Receptor (BCR) (Figure 3F and Supplementary Table 2).

187 We also observed genes belonging to several crucial pathways and biological processes that  
188 had not been previously reported to characterize COVID-19 patients to be underrepresented.  
189 These included EIF2 signaling, with many downregulated genes, such as ribosomal proteins  
190 (RP) and eukaryotic translation initiation factors (EIFs) (Supplementary Figure 3A), common  
191 targets of the integrated stress response (ISR), including antiviral defense<sup>30,31</sup>. In addition,  
192 we also found genes involved in signaling through mTOR (supplementary Figure 3B), a  
193 member of the phosphatidylinositol 3-kinase-related kinase family of protein kinases.  
194 Prediction analysis using Ingenuity pathways showed both lower EIF2 (z-score = - 6.8) and  
195 mTOR (z-score = -2.2) signaling in COVID-19 patients than HDs.

### 196 **Unsupervised whole blood gene expression profiles reveal distinct features of COVID-** 197 **19 patients.**

198 Unsupervised classification of 44 COVID-19 patients and 10 HDs identified three distinct  
199 groups of COVID-19 patients: 10 in group 1, 16 in group 2, and 18 in group 3 (Figure 4).  
200 Detailed patient characteristics according to group are presented in supplementary Table 1.  
201 Among a large set of clinical and biological characteristics, the analysis showed the  
202 differential clustering to not be explained by the severity of the disease. Indeed, the median  
203 Sequential Organ Failure Assessment (SOFA) score and Simplified Acute Physiology Score  
204 (SAPS2), which include a large number of physiological variables<sup>32,33</sup> and evaluate the  
205 clinical severity of the disease (a high score is associated with a worse prognosis) of the  
206 COVID-19 patients, were 6 [4-7] and 36 [28-53], respectively, with no significant differences  
207 between groups. Nevertheless, we observed a significant difference in the median time to  
208 symptoms onset at admission, which ranged from 7 [6 –11] days for patients in group 1 to 11  
209 [10-14] and 13 [9-14] days for patients in groups 2 and 3, respectively (P = 0.04, Kruskal-

210 Wallis test). Finally, group 1 which was the closest to HDs in terms of gene profile, consisted  
211 of patients in the early days of the disease (Supplementary Table 1).

212 Analysis of the genes contributing to the differences between groups confirmed and  
213 extended the findings described above (Figure 3 and Supplementary Figure 3). Several  
214 pathways were highly represented in sectors of the heatmap defined according to gene  
215 abundance across patient groups. For example, 97% of the genes making up the BCR and  
216 65% of those involved in neutrophil responses were represented among the genes showing  
217 a greater abundance in COVID-19 groups 2 and 3 than group 1 and HDs (Figure 4). Other  
218 pathways, such as those for interferon (64%), TCR (100%), iCOS-iCOS-L (88%), mTOR  
219 (81%), and Eif2 signaling (92%) were also highly represented. The interferon signaling  
220 genes, such as IFI44L, IFIT2, and IRF8, a regulator of type I Interferon ( $\alpha$ ,  $\beta$ ), were  
221 significantly more abundant at earlier stages (in patients from group 2) and tended to be less  
222 abundant in group 3, at more advanced stages of the disease. Finally, the abundance of  
223 genes belonging to T-cell pathways (TCR, iCOS-iCOSL signaling) or mTOR and EIF2  
224 signaling was lower in group 3, that is to say, those who were analyzed after a longer time to  
225 symptoms onset. The findings described above highlight the heterogeneity of COVID-19  
226 patients.

227 **Integrative analysis of all biomarkers reveals the major contribution of CD177 in the**  
228 **clinical outcome of COVID-19 patients.**

229 We performed an integrative analysis using all available data to disentangle the relative  
230 contribution of the various markers at the scale of every patient. We thus pooled the data for  
231 29,302 genes from whole blood RNA-seq, cell phenotypes (52 types), and cytokines (71  
232 analytes) using the recently described MOFA approach <sup>34</sup>, which is a statistical framework for  
233 dimension reduction adapted to the multi-omics context. The data are reduced to  
234 components that are linear combinations of variables explaining inter-patient variability  
235 across the three biological measurement modalities. The first component, that we called our  
236 integrative score, discriminated between the three groups of COVID-19 patients and HDs

237 (Figure 5A), although it only explained a portion of the variability within each of the three  
238 types of markers (14% of gene expression, 14% of cell phenotypes, and 5% of cytokines).  
239 The main contributors for the cell phenotype were the significantly lower frequency of cDC2  
240 and T cells and, marginally, the higher number of plasmablasts and CD16<sup>+</sup>  $\gamma\delta$  T cells in  
241 COVID-19 patients (Figure 5B). The contribution of soluble factors was marked by higher  
242 levels of soluble CD163 (sCD163), a marker of polarized M2 macrophages involved in tissue  
243 repair <sup>35</sup>, in more advanced COVID-19 groups (Figure 5C). Indeed, CD163 gene expression  
244 was also significantly higher in COVID-19 patients than HDs (log<sub>2</sub> fold change = +1.55; FDR  
245 = 4.79 10<sup>-2</sup>). sCD163 has also been reported to be a marker of disease severity in critically ill  
246 patients with various inflammatory or infectious conditions <sup>36</sup>. Interestingly, the genes that  
247 contribute the most to the synthesis of this factor were part of the neutrophil module (CD177,  
248 ARG1, MMP9) (Figure 5D). The increasing abundance of CD177 gene expression according  
249 to group was again clearly apparent (Supplementary Figure 4). Integrated analysis also  
250 revealed higher expression of proprotein convertase subtilisin/kexin type 9 (PCSK9). High  
251 plasma PCSK9 levels highly correlate with the development and aggravation of subsequent  
252 multiple organ failure during sepsis <sup>37,38</sup>. Of note, high PCSK9 levels have been recently  
253 associated with severe Dengue infection <sup>39</sup>.

#### 254 **Serum CD177 protein levels are associated with the clinical outcome of COVID-19** 255 **patients.**

256 Given the contribution of the neutrophil activation pathway in the clustering of COVID-19  
257 patients, we sought neutrophil-activation features that could act as possible reliable markers  
258 of disease evolution. We focused on CD177 because: i) it is a neutrophil-specific marker  
259 representative of neutrophil activation, ii) it was the most highly differentially expressed gene  
260 in patients, and iii) the protein can be measured in the serum, making its use as a marker  
261 clinically applicable. Thus, we used an ELISA to quantify CD177 in the serum of 203 COVID-  
262 19 patients (115 patients from the French cohort and 88 patients from the Swiss COVID-19  
263 cohort that we used as “a confirmatory” cohort, patient characteristics are described in Table

264 2), 21% of whom the measurements were repeated (from 2 to 10 measurements per  
265 individual). First, we confirmed the significantly higher median serum protein level in the  
266 global cohort of COVID-19 patients (4.5; [2.2-7.4]) relative to that of 16 HDs (2.2 [0.9-4.2]) ( $P$   
267 = 0.015, Wilcoxon test) (Figure 6A). Second, we found a robust agreement between CD177  
268 gene expression measured by RNA-seq and CD177 protein levels measured by ELISA  
269 (intraclass correlation coefficient 0.88), (Figure 6B).

270 Then, we examined the association of clinical characteristics and outcomes with serum  
271 CD177 concentration at the time of admission. The serum CD177 concentration was  
272 positively associated with the time to symptoms onset ( $P$  = 0.0026) (Figure 6C) and was  
273 higher for patients hospitalized in an ICU (6.0 ng/ml [3.5-9.4] vs 3.3 ng/ml [1.5-5.6],  $P$  <  
274 0.001) (Figure 6D). The association between serum CD177 levels and hospitalization in an  
275 ICU was independent of the usual risk factors, such as age, sex, chronic cardiac or  
276 pulmonary diseases, or diabetes (multivariable logistic regression, adjusted odds ratio 1.14  
277 per unit increase,  $P$  < 0.001). We observed a trend towards a positive association with the  
278 SOFA and SAPS2 risk scores that was not statistically significant ( $P$  = 0.17 and  $P$  = 0.074,  
279 respectively) (supplementary Figure 5A and B). CD177 levels were not associated with other  
280 conditions that contribute to a high risk of severe disease, such as diabetes ( $P$  = 0.632),  
281 chronic cardiac disease ( $P$  = 0.833), chronic pulmonary disease ( $P$  = 0.478), or age of the  
282 patient ( $P$  = 0.83) (data not shown).

283 We then examined the dynamics of the CD177 concentration in 172 COVID-19 patients, with  
284 longitudinal serum samples, using all available measurements (Figure 6E). At the first  
285 measurement, the average concentration of CD177 was not significantly different between  
286 the patients who died and those who recovered (5.93 vs 5.06,  $P$  = 0.26, Wald test). However,  
287 CD177 levels decreased significantly in those who recovered (-0.22 ng/mL/day, 95% CI -  
288 0.307; -0.139), whereas it was stable in those who died (+0.10 ng/mL/day, 95% CI +0.014;  
289 +0.192) and the difference between the two groups was statistically significant (Wald test for  
290 interaction,  $P$  = 0.010). These results show that the stability of CD177 protein levels in severe

291 COVID-19 patients during the course of the disease is a hallmark of a worse prognosis,  
292 leading to death.

## 293 Discussion

294 Here, we investigated factors that influence the clinical outcomes of severe COVID-19  
295 patients involved in a multicentric French cohort combining standardized whole-blood RNA-  
296 Seq analyses, in-depth phenotypic analysis of immune cells, and measurements of a large  
297 panel of serum analytes. An integrated and global overview of host markers revealed several  
298 pathways associated with the course of COVID-19 disease, with a prominent role for  
299 neutrophil activation. This signature included CD177, a specific neutrophil marker of  
300 activation, adhesion to the endothelium, and transmigration. The correlation between CD177  
301 gene abundance and serum protein levels in the blood of COVID-19 patients underscores  
302 the importance of this marker, making the measurement of CD177 levels a reliable approach  
303 that is largely accessible in routine care. We also demonstrated that the dynamics of serum  
304 CD177 levels is strongly associated with the severity of COVID-19 disease, ICU  
305 hospitalization, and survival in an additional cohort of patients.

306 CD177 is a glycosylphosphatidylinositol (GPI)-anchored protein expressed by a variable  
307 proportion of human neutrophils. It plays a key role in the regulation of neutrophils by  
308 modulating their migration and activation. For example, the CD177 molecule has been  
309 identified as the most dysregulated parameter in purified neutrophils from septic shock  
310 patients <sup>40</sup> and in severe influenza <sup>41</sup>. Clinically, neutrophil chemotaxis, infiltration of  
311 endothelial cells, and extravasation into alveolar spaces have been described in lung  
312 autopsies from deceased COVID-19 patients <sup>19</sup>. Elevated CD177 mRNA expression has also  
313 been described for patients with acute Kawasaki Disease (KD) <sup>42</sup> and resistant to IV Ig  
314 therapy <sup>43,44</sup>, a syndrome that has been described as a possible complication of SARS-CoV-2  
315 infection in children <sup>45,46</sup>. Our results are also consistent with those obtained using animal  
316 models, suggesting an important role for neutrophil activation in the severity of infection with  
317 respiratory viruses through their migration towards infected lungs, and in humans infected  
318 with influenza <sup>47-49</sup>.

319 The neutrophil activation signature is a specific feature of the homing of activated neutrophils  
320 toward infected lung tissue in acute lung injury <sup>50</sup>, followed by the initiation of aggressive  
321 responses and the release of neutrophil extracellular traps (NETs), leading to an oxidative  
322 burst and the initiation of thrombus formation <sup>51</sup>. Previous studies have reported elevated  
323 levels of circulating NETs in COVID-19 disease <sup>52</sup>. Consistent with this finding and extending  
324 these data, we showed the differential expression of NET-related genes <sup>41,47,48</sup> (S100A8,  
325 S100A9, and S100A12), confirming the recently described elevated expression of  
326 calprotectin (heterodimer of S100A8 and A9) in severe COVID-19 patients <sup>13</sup>. The  
327 association of neutrophil activation signature with COVID-19 severity has also been  
328 described recently with CD177 gene being one of the most differentially expressed gene in  
329 advanced disease <sup>53</sup>. Although, it is difficult to formally conclude whether CD177 is a causal  
330 factor of disease progression or a consequence of the severity of the disease, our data  
331 strongly show that CD177 is a valid hallmark of the physiopathology of COVID-19. This  
332 observation suggests that the activation of neutrophils, triggered by the infection, is a  
333 fundamental element of the innate response. However, persistent activation of this pathway  
334 may constitute, along with other factors (e.g., “cytokine storm”), fatal harm possibly  
335 associated with the critical turning point in the clinical trajectory of patients during the second  
336 week of the infection.

337 Neutrophil activation was associated with significant changes in the level of gene expression  
338 of several pathways, some concordantly associated with disturbances in immune-cell  
339 populations and cytokine and inflammatory profiles. We reveal a complex picture of the  
340 activation of innate immunity, assessed by significant changes in the expression of several  
341 genes involved in interferon signaling and the response to stress and the production of  
342 inflammatory/activation markers, with a balance between pro-inflammatory signals  
343 (increased expression of IL-1R1, IL-18R1 and its accessory chain IL-18 RAP) and anti-  
344 inflammatory cytokines or regulators (increased expression of IL-10, IL-4R, IL-27, IL-1RN)  
345 <sup>54,55</sup>. The frequency of  $\gamma\delta$  T cells, a subpopulation of CD3<sup>+</sup> T cells that were first described in

346 the lung<sup>56</sup> and that play critical roles in anti-viral immune responses, tissue healing, and  
347 epithelial cell maintenance<sup>57</sup>, was elevated and they expressed an activation marker (CD16)  
348 and low levels of the inhibitory receptor NKG2A, suggesting possible killing capacity. In  
349 accordance with our observation that Eif2 signaling is significantly inhibited in COVID-19  
350 patients, recent studies have shown that coronaviruses encode ISR antagonists, which act  
351 as competitive inhibitors of Eif2 signaling<sup>58,59</sup>. Similarly, the inhibition of mTOR signaling that  
352 we found in COVID-19 patients is consistent with the impaired mTOR signaling reported in  
353 blood myeloid dendritic cells of COVID-19 patients<sup>21</sup>. Interestingly, we observed a markedly  
354 smaller proportion of all DC (pre-DC, pDC, cDC1 and cDC2) and monocyte cell populations,  
355 including classical, intermediate, and non-classical subpopulations, in COVID-19 patients  
356 than in HDs. Based on these observations, it can be hypothesized that the impairment in  
357 IFN- $\alpha$  production observed in severe COVID-19 patients may be the result of both a  
358 decrease in the number of pDCs, which are natural IFN-producing cells<sup>60</sup>, and inhibition of  
359 mTOR signaling, a regulator of IFN- $\alpha$  production, in these cells<sup>61</sup>.

360 We confirmed the previously reported expansion of B-cell populations<sup>21,22</sup> in COVID-19  
361 patients and our results showed that the anti-SARS-CoV-2 B cell repertoire is commonly  
362 mobilized. The marked upregulation of IgV gene families included the IgHV1-24 family,  
363 described to be specific for COVID-19<sup>62</sup>. The expanded VH4-39 family was also recently  
364 reported to be the most highly represented in S-specific SARS-CoV-2 sequences<sup>62</sup>. We also  
365 found enrichment of VH3-33, previously described in a set of clonally related anti-SARS-  
366 CoV-2 receptor-binding domain antibodies<sup>63</sup>.

367 Globally, these results show that the defense against SARS-CoV-2 following pathogen  
368 recognition triggers a fine-tuned program that not only includes the production of antiviral  
369 (Interferon signaling) and pro-inflammatory cytokines but also signals the cessation of the  
370 response and a strong disturbance of adaptive immunity.

371 The same pathways (immune and stress responses through Eif2 signaling, neutrophil and  
372 Interferon signaling, T- and B-cell receptor responses, and mTOR pathways) contributed to

373 the ability to discriminate between three groups of severe COVID-19 patients in an  
374 unsupervised analysis. One limitation of our study was that we did not repeat the RNA-seq  
375 analyses in these specific groups of patients. Nonetheless, it is noteworthy that these groups  
376 differed significantly by the time from disease onset. These findings provide clues in our  
377 understanding of the wide range of profiles previously described for COVID-19 by showing  
378 that these patterns may be mainly related to time-dependent changes in the blood during the  
379 course of the infection <sup>15,64</sup>. For example, the observed lower abundance of IFN signaling  
380 genes in the last group of COVID-19 patients may be due to decreased abundance in more  
381 advanced disease and/or patients who constitutively present a lower abundance of ISG, as  
382 described in previous studies <sup>65</sup>.

383 Several months after the emergence of this new disease, treatment options for patients with  
384 severe disease requiring hospitalization are still limited to corticosteroids, which has emerged  
385 as the treatment of choice for critically ill patients <sup>66,67</sup>. However, interventions that can be  
386 administered early during the course of infection to prevent disease progression and longer-  
387 term complications are urgently needed. A major obstacle for the design of “adapted “  
388 therapies to the various stages of disease evolution is a lack of markers associated with  
389 sudden worsening of the disease of patients with moderate to severe disease and markers to  
390 predict improvement. Our results show that the measurement of CD177 during the course of  
391 the disease may be helpful in following the response to treatment and revision of the  
392 prognosis. In addition, they suggest that therapies aiming to control neutrophil activation and  
393 chemotaxis should be considered for the treatment of hospitalized patients.

## 394 **Materials and Methods**

### 395 **Subjects**

396 We enrolled a subgroup of COVID19 patients of the prospective French COVID cohort  
397 (registered at [clinicaltrials.gov](https://clinicaltrials.gov) NCT04262921) in this immunological study which is part of the  
398 cohort main objectives. Ethics approval was given on February 5th by the French Ethics  
399 Committee CPP-Ile-de-France VI (ID RCB: 2020-A00256-33). Eligible patients were those  
400 who were hospitalized with virologically confirmed COVID-19. Briefly, nasopharyngeal swabs  
401 were performed on the day of inclusion for SARS-CoV-2 testing according to WHO or French  
402 National Health Agency guidelines. Viral loads were quantified by real-time semi-quantitative  
403 reverse transcriptase polymerase chain reactions (RT-PCR) using either the Charité WHO  
404 protocol (testing the E gene and RdRp) or the Pasteur institute assay (testing the E gene and  
405 two other RdRp targets, IP2 and IP4). The study was conducted with the understanding and  
406 the consent of each participant or its surrogate covering the sampling, storage, and use of  
407 biological samples. The Swiss cohort was approved by the ethical commission (CER-VD;  
408 Swiss ethics protocol ID: 2020-00620) and all subjects provided written informed consent.  
409 Blood from healthy donors was collected from the French Blood Donors Organization  
410 (Etablissement Français du sang (EFS)) before the COVID-19 outbreak. HD characteristics  
411 are shown in Supplementary Table 3.

### 412 **Quantification of serum analytes**

413 In total, 71 analytes were quantified in heat-inactivated serum samples by multiplex magnetic  
414 bead assays or ELISA. Serum samples from five healthy donors were also assayed as  
415 controls. The following kits were used according to the manufacturers' recommendations:  
416 LXSAHM-2 kits for CD163,ST2,CD14 and LBP (R&D Systems); the LXSAHM-19 kit for IL-21,  
417 IL-23, IL-31, EGF, Flt-3 Ligand, Granzyme B, Granzyme A, IL-25, PD-L1/B7-H1, TGF- $\alpha$ ,  
418 Aggrecan, 4-1BB/CD137, Fas, FasL,CCL-28, Chemerin, sCD40L, CXCL14, and Midkine  
419 (R&D Systems); and the 48-Plex Bio-Plex Pro Human Cytokine screening kit for IL-1 $\beta$ , IL-  
420 1 $\alpha$ , IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 / CXCL8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17A /

421 CTLA8, Basic FGF (FGF-2), Eotaxin / CCL11, G-CSF, GM-CSF, IFN- $\gamma$ , IP-10/CXCL10,  
422 MCP-1 /CCL2, MIP-1 $\alpha$  / CCL3, MIP-1 $\beta$  / CCL4, PDGF-BB (PDGF-AB/BB), RANTES/CCL5,  
423 TNF- $\alpha$ , VEGF (VEGF-A), IL-1a, IL-2Ra (IL-2R), IL-3, IL-12 (p40), IL-16, IL-18, CTACK /  
424 CCL27, GRO-a /CXCL1 (GRO), HGF, IFN- $\alpha$ 2, LIF, MCP-3 / CCL7, M-CSF, MIF,  
425 MIG/CXCL9, b-NGF, SCF, SCGF-b ,SDF-1 $\alpha$  ,TNF-b/LTA, and TRAIL (Bio-Rad). The data  
426 were acquired using a Bio-Plex 200 system. Extrapolated concentrations were used and the  
427 out-of-range values were entered at the highest or lowest extrapolated concentration. Values  
428 were standardized for each cytokine across all displayed samples (centered around the  
429 observed mean, with variance equal to 1). CD177 quantification was performed on non-  
430 inactivated serum samples (diluted 1:2 or 1:10) using a Human CD177 ELISA Kit  
431 (ThermoFisher Scientific), according to the manufacturer's instructions.

### 432 **Cell phenotyping**

433 Immune-cell phenotyping was performed using an LSR Fortessa 4-laser (488, 640, 561, and  
434 405 nm) flow cytometer (BD Biosciences) and Diva software version 6.2. FlowJo software  
435 version 9.9.6 (Tree Star Inc.) was used for data analysis. CD4<sup>+</sup> and CD8<sup>+</sup> T cells were  
436 analyzed for CD45RA and CCR7 expression to identify the naive, memory, and effector cell  
437 subsets for co-expression of activation (HLA-DR and CD38) and exhaustion/senescence  
438 (CD57and PD1) markers. CD19<sup>+</sup> B-cell subsets were analyzed for the markers CD21 and  
439 CD27. ASC (plasmablasts) were identified as CD19<sup>+</sup> cells expressing CD38 and CD27. We  
440 used CD16, CD56, and Ki57 to identify NK-cell subsets.  $\gamma\delta$  T cells were identified using an  
441 anti-TCR  $\gamma\delta$  antibody. HLA-DR, CD33, CD45RA, CD123, CD141, and CD1c were used to  
442 identify dendritic cell (DC) subsets, as previously described <sup>68</sup>

### 443 **RNA sequencing**

444 Total RNA was purified from whole blood using the Tempus™ Spin RNA Isolation Kit  
445 (ThermoFisher Scientific). RNA was quantified using the Quant-iT RiboGreen RNA Assay Kit  
446 (Thermo Fisher Scientific) and quality control performed on a Bioanalyzer (Agilent). Globin  
447 mRNA was depleted using GlobinClear Kit (Invitrogen) prior to mRNA library preparation with

448 the TruSeq® Stranded mRNA Kit, according to the Illumina protocol. Libraries were  
449 sequenced on an Illumina HiSeq 2500 V4 system. Sequencing quality control was performed  
450 using Sequence Analysis Viewer (SAV). FastQ files were generated on the Illumina  
451 BaseSpace Sequence Hub. Transcript reads were aligned to the hg18 human reference  
452 genome using Salmon v0.8.2<sup>69</sup> and quantified relative to annotation model  
453 "hsapiens\_gene\_ensembl" recovered from the R package biomaRt v2.42.1<sup>70</sup>. Quality control  
454 of the alignment was performed via MultiQC v1.4<sup>69</sup>. Finally, counts were normalized as  
455 counts per million.

### 456 **Statistical analysis**

457 Subgroups of COVID-19 patients were identified from unsupervised hierarchical clustering of  
458 log2-counts-per-million RNA-seq transcriptomics from whole-blood using the Euclidean  
459 distance and Ward's method. Differential expression analysis was carried out using dearseq  
460<sup>71</sup> to contribute to the analysis of genes of which the abundance differed across the three  
461 COVID-19 patient subgroups and healthy subjects. Once the groups were defined by  
462 hierarchical clustering, the analysis of the genes contributing to each group was performed  
463 by selecting genes with an absolute fold-change  $\geq 1.5$  in the comparison of interest for which  
464 the difference in expression between HDs and COVID-19 patients was significant ( $P \leq 0.05$ )  
465 (to avoid so called "double dipping" [<https://arxiv.org/abs/2012.02936>]). Pathway analyses of  
466 the genes involved in each comparison was performed using Ingenuity Pathway Analysis  
467 (IPA®, Qiagen, Redwood City, California, Version 57662101, 2020). For canonical pathway  
468 analysis, a Z-score  $\geq 2$  was defined as the threshold for significant activation, whereas a Z-  
469 score  $\leq -2$  was defined as the threshold for significant inhibition.

470 The integrative analysis of the three types of biological data (RNA-Seq, cell phenotypes,  
471 serum analytes) was performed using MOFA+<sup>34</sup>, a sparse Factor Analysis method. It  
472 provides latent variables which are linear combination of the most influential factors for  
473 explaining inter-patient variability across the three biological measurement modalities. The  
474 first component is presented and called integrative score here. The analyses of factors

475 associated with CD177 protein concentration were performed using non parametric Wilcoxon  
476 test or Spearman correlation coefficient when appropriate. To look at the independent  
477 association of CD177 with ICU, a logistic regression for the prediction of hospitalization in  
478 ICU adjusted for age, sex, chronic cardiac disease, chronic pulmonary disease, diabetes was  
479 fitted. The analysis of repeated measurements of CD177 over time was done by using a  
480 linear mixed effect model adjusted for time from hospitalization and an interaction with  
481 survival outcome (death or recovery). The model included a random intercept and a random  
482 slope with an unstructured matrix for variance parameters. Predictions of marginal  
483 trajectories were performed. All analyses, if not stated otherwise, were performed using R  
484 software version 3.6.3 (R Core Team (2020)). R: A language and environment for statistical  
485 computing. R Foundation for Statistical Computing, Vienna, Austria. URL: [https://www.R-](https://www.R-project.org/)  
486 [project.org/](https://www.R-project.org/)

#### 487 **Data availability**

488 RNA sequencing data that support the findings of this study will be deposited in the Gene  
489 Expression Omnibus (GEO) repository. Other data will be provided as Source data files.

490

491 **Acknowledgments**

492 We thank the patients who donated their blood. We thank F. Mentre, S. Tubiana, the French  
493 COVID cohort, and REACTing (REsearch & ACtion emergING infectious diseases) for cohort  
494 management. We thank the scientific advisory board of the French COVID-19 cohort  
495 composed of Dominique Costagliola, Astrid Vabret, Hervé Raoul, and Laurence Weiss. We  
496 thank Romain Levy for fruitful discussions.

497 **Author Contributions**

498 YL and AW conceived and designed the study. MC, JFT, YY, LB, DB, GP, and MP  
499 participated in sample and clinical data collection. EF, MDe, MS, CLe, and PT performed the  
500 experiments. MD, MG, BH, and CLe analyzed the data. YL, RT, AW, HH, MS, BJH, and CL  
501 analyzed and interpreted the data. YL, RT, AW, and HH drafted the first version and wrote  
502 the final version of the manuscript. All authors approved the final version.

503 **Conflict of interest statement**

504 None of the authors has any conflict of interest to declare.

505 **Funding statement**

506 This work was supported by INSERM and the Investissements d’Avenir program, Vaccine  
507 Research Institute (VRI), managed by the ANR under reference ANR-10-LABX-77-01. The  
508 French COVID Cohort is funded through the Ministry of Health and Social Affairs and  
509 Ministry of Higher Education and Research dedicated COVID19 fund and PHRC n°20-0424  
510 and the REACTing consortium. Funding sources were not involved in the study design, data  
511 acquisition, data analysis, data interpretation, or writing of the manuscript.

512

513

514

515

## 516 References

- 517 1. Coronaviridae Study Group of the International Committee on Taxonomy of, V. The  
518 species Severe acute respiratory syndrome-related coronavirus: classifying 2019-  
519 nCoV and naming it SARS-CoV-2. *Nat Microbiol* **5**, 536-544 (2020).
- 520 2. Phelan, A.L., Katz, R. & Gostin, L.O. The Novel Coronavirus Originating in Wuhan,  
521 China: Challenges for Global Health Governance. *JAMA* (2020).
- 522 3. Wu, Z.Y. & McGoogan, J.M. Characteristics of and Important Lessons From the  
523 Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72  
524 314 Cases From the Chinese Center for Disease Control and Prevention. *Jama-J Am*  
525 *Med Assoc* **323**, 1239-1242 (2020).
- 526 4. Blanco-Melo, D., *et al.* Imbalanced Host Response to SARS-CoV-2 Drives  
527 Development of COVID-19. *Cell* **181**, 1036-1045 e1039 (2020).
- 528 5. Chen, G., *et al.* Clinical and immunological features of severe and moderate  
529 coronavirus disease 2019. *J Clin Invest* (2020).
- 530 6. Kuri-Cervantes, L., *et al.* Immunologic perturbations in severe COVID-19/SARS-CoV-  
531 2 infection. *bioRxiv* (2020).
- 532 7. Mehta, P., *et al.* COVID-19: consider cytokine storm syndromes and  
533 immunosuppression. *The Lancet* **395**, 1033-1034 (2020).
- 534 8. Qin, C., *et al.* Dysregulation of immune response in patients with COVID-19 in Wuhan,  
535 China. *Clin Infect Dis* (2020).
- 536 9. Hadjadj, J., *et al.* Impaired type I interferon activity and inflammatory responses in  
537 severe COVID-19 patients. *Science* **369**, 718-724 (2020).
- 538 10. Mathew, D., *et al.* Deep immune profiling of COVID-19 patients reveals distinct  
539 immunotypes with therapeutic implications. *Science* **369**, eabc8511 (2020).
- 540 11. Wilk, A.J., *et al.* A single-cell atlas of the peripheral immune response in patients with  
541 severe COVID-19. *Nat Med* **26**, 1070-1076 (2020).

- 542 12. Ponti, G., Maccaferri, M., Ruini, C., Tomasi, A. & Ozben, T. Biomarkers associated with  
543 COVID-19 disease progression. *Critical Reviews in Clinical Laboratory Sciences* **57**,  
544 389-399 (2020).
- 545 13. Silvin, A., *et al.* Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate  
546 Severe from Mild COVID-19. *Cell* (2020).
- 547 14. Lucas, C., *et al.* Longitudinal analyses reveal immunological misfiring in severe COVID-  
548 19. *Nature* **584**, 463-469 (2020).
- 549 15. Ong, E.Z., *et al.* A Dynamic Immune Response Shapes COVID-19 Progression. *Cell*  
550 *Host Microbe* **27**, 879-882 e872 (2020).
- 551 16. Giamarellos-Bourboulis, E.J., *et al.* Complex Immune Dysregulation in COVID-19  
552 Patients with Severe Respiratory Failure. *Cell Host Microbe* **27**, 992-1000 e1003  
553 (2020).
- 554 17. Huang, C., *et al.* Clinical features of patients infected with 2019 novel coronavirus in  
555 Wuhan, China. *Lancet* **395**, 497-506 (2020).
- 556 18. Zhou, Z., *et al.* Heightened Innate Immune Responses in the Respiratory Tract of  
557 COVID-19 Patients. *Cell Host Microbe* **27**, 883-890 e882 (2020).
- 558 19. Fu, J., *et al.* The clinical implication of dynamic neutrophil to lymphocyte ratio and D-  
559 dimer in COVID-19: A retrospective study in Suzhou China. *Thrombosis Research* **192**,  
560 3-8 (2020).
- 561 20. Chen, N., *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel  
562 coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* **395**, 507-513  
563 (2020).
- 564 21. Arunachalam, P.S., *et al.* Systems biological assessment of immunity to mild versus  
565 severe COVID-19 infection in humans. *Science* (2020).
- 566 22. Bouadma, L., *et al.* Immune Alterations in a Patient with SARS-CoV-2-Related Acute  
567 Respiratory Distress Syndrome. *J Clin Immunol* (2020).

- 568 23. Yazdanpanah, Y. Impact on disease mortality of clinical, biological, and virological  
569 characteristics at hospital admission and overtime in COVID-19 patients. *Journal of*  
570 *Medical Virology* (2020).
- 571 24. De Biasi, S., *et al.* Marked T cell activation, senescence, exhaustion and skewing  
572 towards TH17 in patients with COVID-19 pneumonia. *Nat Commun* **11**, 3434 (2020).
- 573 25. Xu, B., *et al.* Suppressed T cell-mediated immunity in patients with COVID-19: A clinical  
574 retrospective study in Wuhan, China. *J Infect* **81**, e51-e60 (2020).
- 575 26. Cai, Y.Q., *et al.* Multiple pathophysiological roles of midkine in human disease.  
576 *Cytokine* **135**, 155242 (2020).
- 577 27. Bayat, B., *et al.* Neutrophil Transmigration Mediated by the Neutrophil-Specific Antigen  
578 CD177 Is Influenced by the Endothelial S536N Dimorphism of Platelet Endothelial Cell  
579 Adhesion Molecule-1. *The Journal of Immunology* **184**, 3889-3896 (2010).
- 580 28. Theilgaard-Monch, K. Haptoglobin is synthesized during granulocyte differentiation,  
581 stored in specific granules, and released by neutrophils in response to activation. *Blood*  
582 **108**, 353-361 (2006).
- 583 29. Roth, J., Vogl, T., Sorg, C. & Sunderkötter, C. Phagocyte-specific S100 proteins: a  
584 novel group of proinflammatory molecules. *Trends in Immunology* **24**, 155-158 (2003).
- 585 30. Levin, D. & London, I.M. Regulation of protein synthesis: activation by double-stranded  
586 RNA of a protein kinase that phosphorylates eukaryotic initiation factor 2. *Proc Natl*  
587 *Acad Sci U S A* **75**, 1121-1125 (1978).
- 588 31. Pakos-Zebrucka, K., *et al.* The integrated stress response. *EMBO Rep* **17**, 1374-1395  
589 (2016).
- 590 32. Le Gall, J.R. A new Simplified Acute Physiology Score (SAPS II) based on a  
591 European/North American multicenter study. *JAMA: The Journal of the American*  
592 *Medical Association* **270**, 2957-2963 (1993).
- 593 33. Vincent, J.-L., *et al.* Use of the SOFA score to assess the incidence of organ  
594 dysfunction/failure in intensive care units. *Critical Care Medicine* **26**, 1793-1800 (1998).

- 595 34. Argelaguet, R., *et al.* Multi-omics profiling of mouse gastrulation at single-cell  
596 resolution. *Nature* **576**, 487-+ (2019).
- 597 35. Zhi, Y., *et al.* Clinical significance of sCD163 and its possible role in asthma (Review).  
598 *Mol Med Rep* **15**, 2931-2939 (2017).
- 599 36. Buechler, C., Eisinger, K. & Krautbauer, S. Diagnostic and prognostic potential of the  
600 macrophage specific receptor CD163 in inflammatory diseases. *Inflamm Allergy Drug*  
601 *Targets* **12**, 391-402 (2013).
- 602 37. Boyd, J.H., *et al.* Increased Plasma PCSK9 Levels Are Associated with Reduced  
603 Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis. *J*  
604 *Innate Immun* **8**, 211-220 (2016).
- 605 38. Dwivedi, D.J., *et al.* Differential Expression of PCSK9 Modulates Infection,  
606 Inflammation, and Coagulation in a Murine Model of Sepsis. *Shock* **46**, 672-680 (2016).
- 607 39. Gan, E.S., *et al.* Dengue virus induces PCSK9 expression to alter antiviral responses  
608 and disease outcomes. *J Clin Invest* (2020).
- 609 40. Demaret, J., *et al.* Identification of CD177 as the most dysregulated parameter in a  
610 microarray study of purified neutrophils from septic shock patients. *Immunology Letters*  
611 **178**, 122-130 (2016).
- 612 41. Tang, B.M., *et al.* Neutrophils-related host factors associated with severe disease and  
613 fatality in patients with influenza infection. *Nat Commun* **10**, 3422 (2019).
- 614 42. Huang, W.D., *et al.* Association between maternal age and outcomes in Kawasaki  
615 disease patients. *Pediatr Rheumatol* **17**(2019).
- 616 43. Jing, Y., *et al.* Neutrophil extracellular trap from Kawasaki disease alter the biologic  
617 responses of PBMC. *Biosci Rep* (2020).
- 618 44. Ko, T.M., *et al.* Genome-wide transcriptome analysis to further understand neutrophil  
619 activation and lncRNA transcript profiles in Kawasaki disease. *Sci Rep* **9**, 328 (2019).
- 620 45. Toubiana, J., *et al.* Kawasaki-like multisystem inflammatory syndrome in children  
621 during the covid-19 pandemic in Paris, France: prospective observational study. *BMJ*  
622 **369**, m2094 (2020).

- 623 46. Viner, R.M. & Whittaker, E. Kawasaki-like disease: emerging complication during the  
624 COVID-19 pandemic. *Lancet* **395**, 1741-1743 (2020).
- 625 47. Brandes, M., Klauschen, F., Kuchen, S. & Germain, R.N. A systems analysis identifies  
626 a feedforward inflammatory circuit leading to lethal influenza infection. *Cell* **154**, 197-  
627 212 (2013).
- 628 48. Narasaraju, T., *et al.* Excessive neutrophils and neutrophil extracellular traps contribute  
629 to acute lung injury of influenza pneumonitis. *Am J Pathol* **179**, 199-210 (2011).
- 630 49. Zaas, A.K., *et al.* Gene Expression Signatures Diagnose Influenza and Other  
631 Symptomatic Respiratory Viral Infections in Humans. *Cell Host & Microbe* **6**, 207-217  
632 (2009).
- 633 50. Juss, J.K., *et al.* Acute Respiratory Distress Syndrome Neutrophils Have a Distinct  
634 Phenotype and Are Resistant to Phosphoinositide 3-Kinase Inhibition. *Am J Resp Crit*  
635 *Care* **194**, 961-973 (2016).
- 636 51. Darbousset, R., *et al.* Tissue factor–positive neutrophils bind to injured endothelial wall  
637 and initiate thrombus formation. *Blood* **120**, 2133-2143 (2012).
- 638 52. Barnes, B.J., *et al.* Targeting potential drivers of COVID-19: Neutrophil extracellular  
639 traps. *Journal of Experimental Medicine* **217**(2020).
- 640 53. Aschenbrenner, A.C., *et al.* (2020).
- 641 54. Kim, S.H., Han, S.Y., Azam, T., Yoon, D.Y. & Dinarello, C.A. Interleukin-32: a cytokine  
642 and inducer of TNFalpha. *Immunity* **22**, 131-142 (2005).
- 643 55. Migliorini, P., Italiani, P., Pratesi, F., Puxeddu, I. & Boraschi, D. The IL-1 family  
644 cytokines and receptors in autoimmune diseases. *Autoimmun Rev* **19**, 102617 (2020).
- 645 56. Augustin, A., Kubo, R.T. & Sim, G.K. Resident pulmonary lymphocytes expressing the  
646 gamma/delta T-cell receptor. *Nature* **340**, 239-241 (1989).
- 647 57. Cheng, M. & Hu, S. Lung-resident gammadelta T cells and their roles in lung diseases.  
648 *Immunology* **151**, 375-384 (2017).
- 649 58. Rabouw, H.H., *et al.* Middle East Respiratory Coronavirus Accessory Protein 4a Inhibits  
650 PKR-Mediated Antiviral Stress Responses. *PLoS Pathog* **12**, e1005982 (2016).

- 651 59. Rabouw, H.H., *et al.* Inhibition of the integrated stress response by viral proteins that  
652 block p-eIF2-eIF2B association. *Nat Microbiol* (2020).
- 653 60. Ali, S., *et al.* Sources of Type I Interferons in Infectious Immunity: Plasmacytoid  
654 Dendritic Cells Not Always in the Driver's Seat. *Frontiers in Immunology* **10**(2019).
- 655 61. Kaur, S., *et al.* Regulatory effects of mTORC2 complexes in type I IFN signaling and in  
656 the generation of IFN responses. *Proceedings of the National Academy of Sciences*  
657 **109**, 7723-7728 (2012).
- 658 62. Brouwer, P.J.M., *et al.* Potent neutralizing antibodies from COVID-19 patients define  
659 multiple targets of vulnerability. *Science* **369**, 643-650 (2020).
- 660 63. Barnes, C.O., *et al.* Structures of Human Antibodies Bound to SARS-CoV-2 Spike  
661 Reveal Common Epitopes and Recurrent Features of Antibodies. *Cell* **182**, 828-842  
662 e816 (2020).
- 663 64. Laing, A.G., *et al.* A dynamic COVID-19 immune signature includes associations with  
664 poor prognosis. *Nat Med* (2020).
- 665 65. Bastard, P., *et al.* Autoantibodies against type I IFNs in patients with life-threatening  
666 COVID-19. *Science* **370**, eabd4585 (2020).
- 667 66. Prescott, H.C. & Rice, T.W. Corticosteroids in COVID-19 ARDS. *Jama* **324**, 1292  
668 (2020).
- 669 67. Sterne, J.A.C., *et al.* Association Between Administration of Systemic Corticosteroids  
670 and Mortality Among Critically Ill Patients With COVID-19. *Jama* **324**, 1330 (2020).
- 671 68. See, P., *et al.* Mapping the human DC lineage through the integration of high-  
672 dimensional techniques. *Science* **356**(2017).
- 673 69. Patro, R., Duggal, G., Love, M.I., Irizarry, R.A. & Kingsford, C. Salmon provides fast  
674 and bias-aware quantification of transcript expression. *Nature Methods* **14**, 417-419  
675 (2017).
- 676 70. Durinck, S., Spellman, P.T., Birney, E. & Huber, W. Mapping identifiers for the  
677 integration of genomic datasets with the R/Bioconductor package biomaRt. *Nature*  
678 *Protocols* **4**, 1184-1191 (2009).

679 71. Gauthier, M., Agniel, D., Thiébaud, R. & Hejblum, B.P. dearseq: a variance component  
680 score test for RNA-Seq differential analysis that effectively controls the false discovery  
681 rate. (2019).

682

683

684 **Figure legends**

685 **Figure 1. Frequency of immune-cell subsets between HD (n = 18) and COVID-19**  
686 **patients (n = 50). A** Frequency of total CD3 T cells, CD4 and CD8 T-cell subsets, and  
687 activated CD38<sup>+</sup>HLADR<sup>+</sup> CD8 T cells. **B** Frequency of B-cell subsets (CD21<sup>+</sup>CD27<sup>+</sup>: resting  
688 memory, CD21<sup>-</sup>CD27<sup>+</sup>: activated memory, CD21<sup>-</sup>CD27<sup>-</sup>: exhausted) and plasmablasts  
689 (CD38<sup>++</sup>CD27<sup>+</sup>) gated on CD19<sup>+</sup> B cells. **C** Frequency of NK-cell subsets (gated on CD3<sup>-</sup>  
690 CD14<sup>-</sup>) CD56<sup>Bright</sup>: CD56<sup>++</sup>CD16<sup>+</sup>, CD56<sup>dim</sup>: CD56<sup>+</sup>CD16<sup>++</sup>CD57<sup>+/-</sup>, differentiated Ki67<sup>+</sup> NK  
691 cells (gated on CD56<sup>Bright</sup> or CD56<sup>dim</sup>CD57<sup>-</sup> NK cells) and differentiated Ki67<sup>+</sup> NKT cells  
692 (gated on CD3<sup>+</sup>CD56<sup>+</sup> cells). **D** Monocyte subsets (gated on CD3<sup>-</sup>CD56<sup>-</sup>) (classical  
693 monocytes: CD14<sup>+</sup>CD16<sup>-</sup>, intermediate monocytes: CD16<sup>+</sup>CD14<sup>+</sup>, non-classical monocytes:  
694 CD14<sup>-</sup>CD16<sup>+</sup>). **E** Frequency of  $\gamma\delta$  T cells (gated on CD3<sup>+</sup> T cells) and CD16 and NKG2A  
695 expression (gated on  $\gamma\delta$  CD3 T cells). **F** Frequency of DC subsets (gated on HLADR<sup>+</sup>Lin<sup>-</sup>)  
696 (pDC: CD45RA<sup>+</sup>CD33<sup>-</sup>CD123<sup>+</sup>, pre-DC: CD123<sup>+</sup>CD45RA<sup>+</sup>, cDC1: CD33<sup>+</sup>CD123<sup>-</sup>  
697 CD141<sup>+</sup>CD1c<sup>low</sup>, cDC2: CD33<sup>+</sup>CD123<sup>-</sup>CD14<sup>+</sup>CD1c<sup>+</sup>) detected by flow cytometry in PBMCs  
698 from n = 50 COVID19 patients and n = 18 HDs. The differences between the two groups  
699 were evaluated using Wilcoxon rank sum statistical tests. The lower and upper boundaries of  
700 the box represent the 25% and 75% percentiles, the whiskers extend to the most extreme  
701 data point that is no more than 1.5 times the interquartile range away from the box. Median  
702 values (horizontal line in the boxplot) are shown.

703 **Figure 2. Heatmap of analyte abundance in serum.** The colors represent standardized  
704 expression values centered around the mean, with variance equal to 1. HD: healthy donors  
705 (n = 5), COVID: COVID19 patients (n = 33). Each column represents a subject. Each line  
706 represents an analyte.

707 **Figure 3. Whole blood gene expression in COVID-19 patients and HDs. A.** Volcano plot  
708 showing differentially expressed genes (DEG) according to the log<sub>2</sub> fold change (log<sub>2</sub> FC)  
709 and Benjamini-Hochberg False Discovery Rate (FDR) with thresholds at absolute log<sub>2</sub> FC  $\geq$   
710 log<sub>2</sub>(1.5) and FDR  $\leq$  0.05. **B** Main top DEG related to neutrophils. **C** and **D** Main DEG related

711 to IFN and interleukin responses, respectively. **E** Main TCRV T-cell repertoire DEG **F** Main  
712 B-cell IGHV repertoire DEG. Red symbols represent overabundant genes in COVID-19  
713 relative to HD, green symbols represent underabundant genes.

714 **Figure 4. Heatmap of standardized gene expression.** The colors represent standardized  
715 expression values centered around 0, with variance equal to 1. Each column represents a  
716 subject. This heatmap was built by unsupervised hierarchical clustering of log2-counts-per-  
717 million RNA-seq transcriptomic data from whole blood (29,302 genes) and subjects (n = 54)  
718 using the Euclidean distance and Ward's method. Seven blocks are highlighted according to  
719 the features of gene expression across the groups of individuals. Enrichment (number and %  
720 of genes of a given pathway selected in the block) of pathways of interest are shown for each  
721 block.

722 **Figure 5. Integrative analysis.** Integrative analysis of the data of RNA-seq (29,302 genes)  
723 from 44 COVID-19 patients, cell phenotype (52 types) from 45 COVID-19 patients, and  
724 serum analytes (71 analytes) from 33 COVID-19 patients using a sparse principal component  
725 analysis approach, MOFA v2. **A** Integrative score according to the patient groups defined by  
726 the hierarchical clustering of the RNA-seq data. Top 10 marker contributions (according to  
727 the weight from -1 to 1) of the cell phenotypes (**B**), serum analytes (**C**), and RNA-seq (**D**).  
728 The integrative score corresponds to the first factor of the analysis and allows the ordering of  
729 individuals along an axis centered at 0. Individuals with an opposite sign for the factor  
730 therefore have opposite characteristics.

731 **Figure 6: Distribution of the CD177 marker and association with clinical outcomes of**  
732 **COVID-19 patients. A** Measurement of CD177 (ng/ml). HD: Healthy donors (n = 16),  
733 COVID-19 patients (n = 203). The difference between the two groups was evaluated using  
734 Wilcoxon rank sum statistical tests. The median values (horizontal line in the boxplot) are  
735 shown. The lower and upper boundaries of the box represent the 25% and 75% percentiles.  
736 **B** Correlation between normalized CD177 values of gene expression measured by RNA-seq  
737 and CD177 protein by ELISA (ng/ml) from 36 COVID-19 patients. The blue line represents

738 the linear regression line and the grey area the 95% prediction confidence interval. **C**

739 Association between CD177 serum concentration and time from symptoms onset (n = 192).

740 This association was tested using Spearman correlation tests. The blue line represents the

741 linear regression line and the grey area the 95% confidence interval. **D** Measurement of

742 CD177 serum concentration in patients hospitalized in an intensive care unit (ICU) or not (n =

743 196). Wilcoxon rank tests were used. The median values (horizontal line in the boxplot) are

744 shown. The lower and upper boundaries of the box represent the 25% and 75% percentiles.

745 **E.** Change of CD177 concentration over time according to the occurrence of death for 172

746 COVID-19 patients and a total of 248 measurements. Predictions were calculated using a

747 mixed effect models for longitudinal data.

748

749

750

751

752

753

754 **Table 1. Patient characteristics of the French COVID cohort (n=61)**

		No.
<b>Demographic characteristics</b>		
Age - Median (IQR) - years	61	60 (50 - 69)
Male sex – No./total No. (%)	61	49/61 (80)
ICU or transfer to ICU or death – No./total No. (%)	61	53/61 (87)
Outcome – No./total No. (%)	61	
Death		21/61 (34)
Discharge alive		40/61 (66)
<b>Median interval from first symptoms on admission (IQR)-days</b>	61	11 (7 - 14)
<b>Comorbidities – No./total No. (%)</b>		
Any	61	14/61 (23)
Chronic cardiac disease	61	9/61 (15)
Hypertension	61	22/61 (36)
Chronic pulmonary disease	61	5/61 (8)
Asthma	61	4/61 (7)
Chronic kidney disease	61	6/61 (10)
Chronic neurological disorder	61	2/61 (3)
Obesity	60	23/60 (38)
Diabetes	61	12/61 (20)
<b>Smoking History – No./total No. (%)</b>		
Smoking	61	5/61 (8)
<b>Laboratory findings on admission - Median (IQR)</b>		
Hemoglobin - g/dL	57	13 (11 - 14)
WBC count - x10 <sup>9</sup> /L	57	6 (5 - 9)
Platelet count - x10 <sup>9</sup> /L	57	189 (143 - 270)
C-reactive protein (CRP) - mg/L	57	120 (66 - 195)
Blood Urea Nitrogen (urea) - mmol/L	57	7 (5 - 12)
<b>Symptoms on admission - No./total No. (%)</b>		
Fever	59	51/59 (86)
Cough	57	40/57 (70)
Sore throat	56	4/56 (7)

Wheezing	54	6/54 (11)
Myalgia	56	21/56 (38)
Arthralgia	55	9/55 (16)
Fatigue	57	27/57 (47)
Dyspnea	57	46/57 (81)
Headache	57	11/57 (19)
Altered consciousness	56	3/56 (5)
Abdominal pain	53	8/53 (15)
Vomiting / nausea	56	10/56 (18)
Diarrhea	56	11/56 (20)

### **Clinical characteristics on admission -**

#### **Median (IQR)**

SOFA score (ICU patients)	34	6 (4 - 8)
SAPS2 (ICU patients)	36	32 (27 - 53)
Heart rate - beats per minute	61	87 (76 - 104)
Respiratory rate - breaths per minute	55	24 (20 - 32)
Systolic blood pressure - mmHg	60	130 (109 - 145)
Diastolic blood pressure - mmHg	60	77 (70 - 87)
Oxygen saturation - percent	61	96 (91 - 98)
Oxygen saturation on – No./total No. (%)	56	
Room air		17/56 (30)
Oxygen therapy		39/56 (70)


#### **Treatments – No./total No. (%)**




Antiviral	60	40/60 (66)
Antibiotic	60	46/60 (77)
Corticosteroids	60	33/60 (55)
Antifungal	60	9/60 (15)
Hydroxychloroquine	59	8/59 (14)

755 **Table 2. Characteristics of patients involved in the CD177 analysis**


756

	No.	French cohort (n = 115)	Swiss cohort (n = 88)
<b>Demographic characteristics</b>			
Age - Median (IQR) - years	200	62 (54-72)	63 (57-74)
Male sex - No./total No. (%)	201	82/113 (73)	56/88 (64)
ICU or transfer to ICU or death - No. /total No. (%)	200	61/112 (54)	40/88 (45)
Outcome - No. /total No. (%)	173		
Death		32/107 (30)	8/66 (12)
Discharge alive		75/107 (70)	58/66 (88)
<b>Median interval from first symptoms on admission (IQT)</b>	192	13 (9-18)	12 (9-17)
<b>Comorbidities - No./total No. (%)</b>			
Chronic cardiac disease	197	22/109 (20)	25/88 (28)
Chronic pulmonary disease	197	14/109 (13)	9/88 (10)
Diabetes	197	23/109 (21)	26/88 (30)
<b>Laboratory findings on admission - Median (IQR)</b>			
C-reactive protein (CRP) - mg/L	34	122 (62-196)	
Lactate dehydrogenase (LDH) UI/L	31	466 (337-533)	
<b>Clinical characteristics on admission - Median (IQR)</b>			
Score SOFA	41	4 (2-7)	
Score SAPS2	40	32 (27-49)	



**D****E****F**


761 Figure 2



762



777 Figure 4



778


779

780


781

782


**A**




**B**



**C**



**D**



785 Figure 6

